Education
About Us
Working with TipRanks
Follow Us
Veradermics, Incorporated (MANE)
:MANE
MANE Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
MANE FAQ
What was Veradermics, Incorporated’s price range in the past 12 months?
Currently, no data Available
What is Veradermics, Incorporated’s market cap?
Currently, no data Available
When is Veradermics, Incorporated’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Veradermics, Incorporated’s earnings last quarter?
Currently, no data Available
Is Veradermics, Incorporated overvalued?
According to Wall Street analysts Veradermics, Incorporated’s price is currently Undervalued.
Does Veradermics, Incorporated pay dividends?
Veradermics, Incorporated does not currently pay dividends.
What is Veradermics, Incorporated’s EPS estimate?
Veradermics, Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Veradermics, Incorporated have?
Veradermics, Incorporated has 33,350,170 shares outstanding.
What happened to Veradermics, Incorporated’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Veradermics, Incorporated?
Currently, no hedge funds are holding shares in MANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Veradermics, Incorporated
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.